General Information of the Compound
Compound ID |
CP0011191
|
||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Compound Name |
4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzene-1-sulfonamide
Show/Hide
|
||||||||||||||||||
Synonyms |
4-(5-(4-Methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl)benzenesulfonamide
4-[5-(4-METHYLPHENYL)-3-(TRIFLUOROMETHYL)-1H-PYRAZOL-1-YL]BENZENESULFONAMIDE
4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1Hpyrazol-1-yl] benzenesulfonamide
4-[5-(4-methylphenyl)-3-(trifluoromethyl)pyrazol-1-yl]benzenesulfonamide
AI-525
Benzenesulfonamide,4-(5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl)
CEL
CEP-33222
Celebra
Celebra (TN)
Celebrex
Celebrex (TN)
Celebrex, Celebra, Celecoxib
Celecox
Celecoxi
Celecoxib
Celecoxib (JAN/USAN/INN)
Celecoxib (SC-58635)
Celecoxib [Old RN]
Celecoxib [USAN]
Celocoxib
Eurocox
Medicoxib
Onsenal
P-(5-p-Tolyl-3-(trifluoromethyl)pyrazol-1-yl)benzenesulfonamide
PMID26394986-Compound-22
Pfizer brand of celecoxib
SC 58635
SC-58553, SC-58635
SC-58635
SC58635
Solexa
TPI-336
Xilebao
YM 177
YM-177
YM177
Show/Hide
|
||||||||||||||||||
Structure |
|
||||||||||||||||||
Formula |
C17H14F3N3O2S
|
||||||||||||||||||
Molecular Weight |
381.379
|
||||||||||||||||||
Canonical SMILES |
Cc1ccc(cc1)-c1cc(nn1-c1ccc(cc1)S(N)(=O)=O)C(F)(F)F
Show/Hide
|
||||||||||||||||||
InChI |
InChI=1S/C17H14F3N3O2S/c1-11-2-4-12(5-3-11)15-10-16(17(18,19)20)22-23(15)13-6-8-14(9-7-13)26(21,24)25/h2-10H,1H3,(H2,21,24,25)
Show/Hide
|
||||||||||||||||||
InChIKey |
RZEKVGVHFLEQIL-UHFFFAOYSA-N
|
||||||||||||||||||
CAS |
169590-42-5
184007-95-2
194044-54-7
|
||||||||||||||||||
Physicochemical Property |
"RO5" indicates the cutoff set by lipinski's rule of five: (1) Molecular weight less than 500 Dalton; (2) xlogp less than 5; (3) No more than 5 hbonddonor (Hydrogen Bond Donor Count); (4) No more than 10 hbondacc (Hydrogen Bond Acceptor Count); (5) No more than 10 rotbonds (Rotatable Bond Count). Show/Hide
|
||||||||||||||||||
Click to Show/Hide the External Link(s) of This Compound | |||||||||||||||||||
PubChem ID | |||||||||||||||||||
ChEMBL ID | |||||||||||||||||||
DrugBank ID |
Map of Molecular Bioactivity Related to the Compound
Map of Molecular Bioactivity Related to the Compound Compound Cell Line Protein Bioactivity Value: <= 0.1 μM > 0.1 μM and <= 10 μM > 10 μM Imprecise Activity |
|
---|
Table of Molecular Bioactivities Related to the Compound
Protein ID: PT00209, Carbonic anhydrase
Protein ID: PT01176, cGMP-specific 3',5'-cyclic phosphodiesterase
Protein ID: PT02932, Cytochrome c oxidase subunit 2
Protein ID: PT00817, Cytochrome P450 2D6
Protein ID: PT06109, Geminin
Protein ID: PT00991, Histone deacetylase 1
Protein ID: PT01213, Histone deacetylase 6
Protein ID: PT02997, Isocitrate dehydrogenase [NADP] cytoplasmic
Protein ID: PT02025, Prostaglandin E synthase
Protein ID: PT00940, Prostaglandin G/H synthase 1
Cell-based Assay
Biochemical Assays
Protein ID: PT01898, Prostaglandin G/H synthase 1
Protein ID: PT00901, Prostaglandin G/H synthase 2
Cell-based Assay
Biochemical Assays
Protein ID: PT01062, Prostaglandin G/H synthase 2
Cell-based Assay
Cell Viability or Cytotoxicity Assay
Cell Line ID | Cell Line Name | Cell Line Organism | |
CL000068 | A-549 | Homo sapiens (Human) | 1 |
1 |
IC50 = 15600 nM
|
TI
LI
LO
TS
|
|
---|---|---|---|
CL000141 | LNCaP | Homo sapiens (Human) | 1 |
1 |
IC50 = 50400 nM
|
TI
LI
LO
TS
|
Clinical Information about the Compound
Drug 1 ( Celecoxib )
Drug Name | Celecoxib | ||
---|---|---|---|
Company | Pfizer | ||
Indication | |||
Target(s) |
Prostaglandin G/H synthase 2 (COX-2)
Inhibitor
|